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The European Myelofibrosis Network (EUM-
NET), a European research network on my-
elofibrosis with myeloid metaplasia (MMM),
has developed a definition of response for
the disease by using clinicohematologic,
histologic, and cytogenetic criteria. A core
set of 5 clinicohematologic criteria was se-
lected out of 9 candidates on the basis of
their sensitivity to change measured in 196
patients treated either during clinical trials
or routine clinical practice. A consensus
panel of 16 international experts was con-
vened and asked to score the level of re-
sponse in 104 patient profiles as major,
moderate, minor, or no response according
to changes of the clinicohematologic crite-
ria. Using the experts’ consensus as the
gold standard, the performance of 100 pos-
sible definitions of response was evaluated.
Criteria for major or moderate clinicohema-
tologic response were determined to be
changes in hemoglobin (Hb) and spleen size
and the presence of constitutional symp-
toms, while changes in platelet count and
white blood cell (WBC) count served as
complementary criteria and were of value
for defining minor responses. A histologic
response was defined by changes in bone
marrow fibrosis and cellularity grades. The
combined use of these response definitions
should help standardize the design and re-
porting of future clinical studies in MMM.
(Blood. 2005;106:2849-2853)
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Introduction
Myelofibrosis with myeloid metaplasia (MMM) is a clonal disorder
of hematopoiesis categorized in the spectrum of chronic myelopro-
liferative diseases (CMPDs).1,2 The need to unequivocally distin-
guish patients with MMM from those with other CMPDs has led ad
hoc committees to develop diagnostic criteria.3,4
The responses of MMM to therapies, in terms of improved
well-being and survival, have to date been evaluated by separately
analyzing single clinical, hematologic, or histologic parameters
and, as a result, different definitions of response have been
proposed.5-11 There is, therefore, a pressing need for the develop-
ment of standardized criteria for monitoring and assessing treat-
ment responses, especially for the conduct of clinical research and
for comparing the outcome of different clinical trials.
Because standard therapies have not been shown to prolong the
overall survival of patients with MMM, the current approach is a
conservative one aimed at palliation of anemia, systemic symptoms,
and symptomatic splenomegaly. However, new therapies are now
available that may affect the natural course of the disease.8-10 More-
over, ablation of the abnormal hematopoietic clone with high-dose
chemotherapy and allogeneic stem cell transplantation offers a
chance to achieve a cure in MMM.11 Thus, assessment of the response
should reflect the specific aims of the treatment, and responses
should be graded for both palliative and disease-modifying therapies.
Perceiving the need for the development of rigorous, consistent,
and feasible criteria for the response assessment of patients with
MMM, European investigators funded by a European Community
Concerted Action (European Myelofibrosis Network [EUMNET])
grant collaborated to define the quality and degree of response in
MMM. The final goal was to develop a definition of response that
would be applicable to future clinical studies as well as in routine
clinical practice. This report represents the recommendations from
the EUMNET working group and from international experts who
participated in the final consensus conferences (CCs).
Patients, materials, and methods
The EUMNET project’s response criteria were developed by using a
multistep process based on a modified National Institutes of Health (NIH)
approach.12 An 18-member advisory board (AB) constituted in November
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2002 was composed of experienced clinicians and pathologists and was
chaired by 3 clinicians with clinical epidemiology expertise. The objectives
of the AB were to define the aims of the project, to frame the operative
context, to select the members of the CC panels, and to organize the
consensus development process aimed at defining the response definitions.
After the initial meetings, the AB agreed on the aim of the project: “to
develop a definition of response to treatment in patients with MMM for the
clinico-hematological, histological and cytogenetic categories” (Table 1).
Clinicohematologic definition of response
A questionnaire was mailed to all members of the AB asking them to
suggest candidate criteria for use in the definition of clinicohematologic
response and, in a second questionnaire, to rank the top 9 choices among
candidate criteria. All the questionnaires were returned, and the candidate
criteria were ranked according to their priority votes, with the 9 criteria that
ranked highest forming the preliminary core set of criteria.
The validity of the clinicohematologic criteria as sensitive and specific
tools to measure response to treatments was tested in 196 patients reported
from 9 cooperative institutions. Many of the patients had been included in
prospective therapeutic trials evaluating experimental agents, including
standard-dose thalidomide, low-dose thalidomide, pegilated interferon, and
imatinib. The remaining patients had been treated with hydroxyurea under
current clinical practice. In all the cases, the clinical information available
at the start of treatment allowed classification according to the Dupriez
prognostic score.13 The median age was 56 years (range, 24 to 72 years),
and 107 patients were men. The 9 criteria of the core set were monitored
regularly and, to allow comparability, week 24 was chosen for the final
analysis. Sensitivity to change of the noncategorical parameters was
evaluated using the standardized response mean (SRM).14 The difference
between the values of the criteria obtained at the first and last visit was
determined. SRM was calculated as the ratio between the mean and the
standard deviation of the difference, with levels above 0.8 denoting high
sensitivity to change.14 The strength of association of the changes during
therapy of each parameter was also measured by the correlation statistics.
Based on the results of the sensitivity to change analysis, the AB
proposed a final core of 5 criteria and for each of these criteria proposed a
definition of response (complete or partial) and of progression.
Five international scientists were asked to join the AB to form an expert
panel for the consensus conference (CC). The panel was composed of
experts in clinical medicine, clinical research, pathology, outcomes/health
services research, and medical decision-making. The clinical experts were
from the fields of hematology and medical oncology, and both academic
and hospital representatives were included. The panelists were provided
with a booklet that summarized the goals of the project and the results of the
questionnaire phases. The statistical performance was included for all 5
criteria of the final core set.
The CC was held in Vienna on October 18-19, 2004. The meeting was
attended by the members of the CC panel with the assistance of 3 members
of the AB (G.B., M.M., N.L.L.). The overall goal of the meeting was to
decide on the definition of clinicohematologic response based on the 5 core
criteria using a combination of statistical and consensus formation tech-
niques. Existing databases were exploited to build 104 patient profiles in
which the absolute values at the start and at the end of treatment were
shown for each criterion. The patient profiles were presented to conference
attendees and, using the nominal group technique,15 participants at the CC
were asked to individually rate each of the patients as either a responder or
nonresponder as well as to choose the category of response as major,
moderate, minimal, or no response. The moderator asked each member how
she/he had voted on each profile. If an 80% consensus was not achieved, the
patient profile was discussed in round-robin fashion and a second vote
taken. If an 80% consensus was still not attained, the patient profile was
declared uninterpretable and was not considered further. By using combina-
tions of the core criteria, the AB developed for testing a set of 100 sound
definitions of clinicohematologic response for MMM. The ability of the 100
candidate definitions to classify individual patients as having major,
moderate, minor, or no response was evaluated, and the agreement between
the classification based on the definitions and the consensus of the
physicians was assessed. Using the physicians’ consensus judgment as the
gold standard, percent false positive and false negative rates, 2, sensitivity,
and specificity for each of the 100 definitions of response for MMM were
calculated. Only patient profiles for which physician consensus was
achieved were used. Definitions of response showing either a sensitivity or
specificity of less than 80% were eliminated from further consideration. We
used the  statistic as an additional measure of agreement between the
physicians’ evaluation16 and the definitions:  values 0.7 or above were
considered to be evidence of agreement.
Definition of histologic response
The definition of histologic response was dependent on grading of bone
marrow fibrosis and bone marrow cellularity. A CC was organized in
Palermo on October 28-31, 2004. The meeting was attended by 2
pathologists of the AB and 11 European hematopathologists. All the 13
experts reviewed, using a multiheaded microscope, more than 150 trephine
biopsy samples from various medical institutions. Specimens included
different lesions but were predominantly cases of CMPDs before and after
therapy. Assessment of parameters was made by using a multiple eyepiece
microscope, and grading was performed in an independent fashion by each
participant. Consensus was assumed when at least 11 of the 13 pathologists
achieved the same scoring.
Definition of cytogenetic response
The AB of this project discussed and decided to adopt the cytogenetic
response criteria already published for myelodysplastic syndromes.17
Results
Selection of the criteria and of the best definition for the
clinicohematologic response
The AB listed 16 criteria to be included as candidate criteria for the
clinicohematologic response assessment in patients with MMM.
The 9 criteria with the highest preference rate from the question-
naire as the core set of criteria to use during therapy evaluation
were hemoglobin (Hb) (score 130), spleen size (score 100), platelet
count (score 84), absolute number of CD34 cells in peripheral
blood (score 76), white blood cell (WBC) count (score 70),
percentage of blasts in peripheral blood (score 69), serum lactate
dehydrogenase (LDH) level (score 60), quality of life (score 54),
and constitutional symptoms (score 50).
The Dupriez prognostic score for the 196 patients enrolled into
the study of sensitivity to change of the core set of parameters was
low for 67 patients, intermediate for 103 patients, and high for 26
patients. While all 196 patients included in the protocol had
repeated evaluation of Hb, spleen size, WBC count, and platelet
count, only 115 of 196 had repeated enumeration of CD34 cells in
peripheral blood and 96 of 196 had repeated measurement of LDH
and percentage of blasts in peripheral blood. By considering the
Table 1. Categories of response
1. Clinicohematologic response
2. Histologic bone marrow response
3. Cytogenetic response
These categories should be applied to patients with MMM (both idiopathic and
post-polycythemia vera [post-PV] or post-essential thrombocythemia [post-ET] myelo-
fibrosis) receiving both palliative and disease-modifying therapies. The 3 categories
of response should be used in a cumulative sequential manner starting from the
clinicohematologic response (thus representing the minimal set of criteria to be
evaluated for assessing response). The decision to use a composite definition of
response (clinicohematologic and histologic response; or clinicohematologic, histo-
logic, and cytogenetic response) will depend on the goal of the therapy.
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whole population of patients, no parameter had an SRM of 0.8 or
more, and SRM was more than 0.3 for Hb, spleen size, and
CD34-cell number in peripheral blood. However, in specific
patient subsets (Table 2), SRM was more than 0.5 for Hb, LDH,
and spleen size. Regression analysis indicated a significant associa-
tion (P  .01) between changes of spleen size and of number of
blasts and between changes in CD34 cells in peripheral blood and
LDH. Face validity (ie, a subjective judgment of clinical appropri-
ateness) and content validity (ie, a subjective judgment of the
relevance of the individual candidate criteria) were analyzed and
discussed by the AB. Taking into account SRM and validity
judgments, the final core set to be used in the clinicohematologic
response included 5 of the 9 criteria (Table 3). Quality of life
measures, CD34-cell count in peripheral blood, and serum LDH
were recommended as independent parameters to be evaluated
during clinical trials but not to be included in the response
definition.
During the Vienna CC, the 16 panel members, using the
patient profiles, scored 23 of the 84 patients as having a major
response, 22 as having a moderate response, 9 as having a
minimal response, 17 as having no response, and 13 as
uninterpretable. Eight of the 100 definitions of response showed
2 more than 10. The definitions of response that scored highest
are reported in Table 4.
Definition of histologic response
The results of the Palermo meeting for grading of bone marrow
fibrosis and assessment of cellularity are reported in detail
elsewhere.18 In summary, it was agreed that the basic require-
ment for assessment of cellularity is a representative biopsy,
defined as an artifact-free, nontangential sample at least 1.5 cm
long. In addition, the optimal thickness of the paraffin sections
should be 3 to 4 m, and the cellularity should be documented in
relation to age and with respect to normally occurring ranges
(Table 5). Quantity and quality (reticulin/collagen) of the fiber
content should be determined only in areas of hematopoiesis by
using a scoring system comprising 4 grades (Table 6). Recom-
mendations for applying the scoring system included firstly to
assess the quality of the reticulin stain by detection of normal
staining in vessel walls as internal controls. Furthermore,
lymphoid nodules and vessels as well as fibers framing adipo-
cytes should be disregarded. Finally, areas of prominent sclere-
dema (ie, gelatinous edema showing a tendency to develop a
discrete reticulin fibrosis) and/or scarring should be included in
the overall grading of myelofibrosis.
The AB decided that a histologic response should be defined
both for cellularity and for bone marrow fibrosis and that grading of
the response should reflect the grading difference between begin-
ning and end of therapy.
Table 2. Performance of the candidate clinicohematologic criteria
Criterion Pretreatment value No. of patients SRM
Hb level  100 g/L 86 0.67
Spleen size  10 cm below the left
costal margin
89 0.58
Platelet count  150 109/L 71 0.40
CD34 count  100 106/L 67 0.39
WBC count  25 109/L 20 0.09
Blasts in peripheral
blood
 5% 32 0.17
LDH  3 times normal 14 0.56
SRM indicates standardized response mean.
Table 3. Definition of response for each core clinicohematologic criterion
Criterion Complete response Partial response Progression
Hemoglobin (Hb) level Hb 120 g/L for patients with Hb  100 g/L; or
achievement of transfusion independence,
with stable Hb  110 g/L, for RBC
transfusion-dependent patients
Increase of Hb 20 g/L (but Hb  120 g/L)
for non-RBC transfusion-dependent
patients; or reduction 50% of
transfusion requirement for RBC
transfusion-dependent patients
Decrease of Hb 20 g/L or transfusion
requirement for non-RBC
transfusion-dependent patients; or
increase 50% of transfusion
requirement for RBC transfusion-
dependent patients
Splenomegaly* Spleen not palpable Decrease of spleen size  50% in patients
with spleen size 10 cm from the left
costal margin; or decrease of spleen size
 30% in patients with spleen size 10
cm from the left costal margin
Increase of spleen size 50% in
patients with spleen size 10 cm
from the left costal margin; or
increase of spleen size 30% in
patients with spleen size  10 cm
from the left costal margin
Constitutional
symptoms†
Absence of constitutional symptoms n/a Appearance of constitutional symptoms
Platelet (PTL) count PTL count 150 109/L to 400 109/L Decrease of PTL count 50% without
normalization in patients with PTL
count  800 109/L; or increase of PTL
count 50 109/L without
normalization for patients with PTL
count  100 109/L
n/a
White blood cell
(WBC) count
WBC count 4 109/L to 10 109/L Decrease of WBC count 50% without
normalization in patients with WBC
count  20 109/L; or increase of WBC
count 1 109/L without normalization
in patients with WBC count  4 109/L
n/a
Values must be stable for at least 4 weeks.
n/a indicates not applicable.
*Measured in cm below the left costal margin.
†Unexplained recurrent fever 38.0°C or above, drenching night sweats, or 10% or more body weight loss.
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Definition of cytogenetic response
The assessment of cytogenetic response was recommended to be
dependent on the analysis of 20 metaphases using conventional
cytogenetic techniques. A major response was defined as the failure
to detect a cytogenetic abnormality in those cases with a preexist-
ing abnormal karyotype, while a minor response was defined as a
50% or greater reduction in abnormal metaphases. Fluorescence in
situ hybridization may be used as a supplement to follow a specific
defined cytogenetic abnormality.
Discussion
In clinical research, the clinicohematologic, histologic, and cytoge-
netic responses to new therapeutic agents for MMM are the most
important objective, and response rates may provide support for
approval by regulatory agencies. In this work, we provide response
definitions that are valuable for assessing the clinical outcomes of
different therapeutic strategies in MMM, from palliative therapies
to therapies altering the natural history of the disease. The
assumption of this project is that the assessment of the response to
treatments in MMM may be a priori graded according to trial
designs and outcomes, from the unique clinicohematologic re-
sponse to an extended definition of response, including histologic
and cytogenetic evaluation.
In the absence of a specific biologic marker for the disease, a
definition of response in MMM is a complex issue necessitating the
incorporation of multiple criteria. The task is further complicated
by the paucity of trials and ad hoc studies that have reported the
statistical information needed to synthesize the evidence. We used a
combination of statistical and consensus methodologies for best
definitions of improvement. The core set of candidate clinicohema-
tologic criteria identified by the AB was further modified according
to their sensitivity to change and to face and construct validity. The
results of the CC suggest that patients with MMM, when evaluated
for the clinicohematologic response, should be assessed first
according the variations of 3 major criteria: anemia, spleen size,
and constitutional symptoms. Variations in platelet count and WBC
count were identified as minor criteria that may serve to define a
minor response to therapy.
Three other criteria were selected in the early phase of this project as
having importance in the assessment of response to treatment. They
were quality of life, CD34 cells in peripheral blood,19 and serum
LDH. The first is of importance in therapies that do not impact on
disease progression but on patient well-being. The 2 other parame-
ters are biomarkers that serve as response criteria for myeloprolif-
eration. However, the AB deemed their reliability and applicability
not to fit with a clinically consistent definition of response, and they
were not included in the response definition but were recom-
mended as monitoring parameters during experimental therapies.
Monitoring the changes in bone marrow histology after a period
of treatment is not routine in clinical practice and in clinical trials.
However, drugs that promise to change the natural course of the
disease need to be assessed for their impact on histopathology of
the bone marrow. The most frequently used grading systems for
bone marrow fibrosis are based on the Bauermeister scale,20
modified by Manoharan et al.21 A consensus panel simplified these
previous descriptions of scorings of fiber density by reducing them
to 4 grades, including the normal reticulin density, to reduce
overlapping among the grades and to achieve a higher degree of
reproducibility in routine diagnosis. Confusion created in former
systems, wherein normal reticulin is classified as “grade 1,” was
reduced by classifying normal reticulin as “grade 0.”
Chromosomal alterations in MMM have a major biologic and
prognostic relevance. The therapeutic agents in use today are not able to
modify the frequency of chromosomal abnormalities. However,
high-dose chemotherapy followed by stem-cell transplantation is a
Table 4. Definition of clinicohematologic response
Response type Definition
Complete response Complete response in all the criteria
Major response Provided that the criteria for complete response are not
satisfied:
1. Any response in anemia and splenomegaly without
progression in constitutional symptoms, OR
2. Complete response in anemia, or partial response in
anemia that is transfusion dependent, and response
in constitutional symptoms without progression in
splenomegaly, OR
3. Any response in splenomegaly and response in
constitutional symptoms without progression in
anemia
Moderate response Provided that the criteria for major response are not
satisfied:
1. Complete response in anemia with progression in
splenomegaly, OR
2. Partial response in anemia without progression in
splenomegaly, OR
3. Any response in splenomegaly without progression
in anemia and constitutional symptoms
Minor response Provided that the criteria for moderate response are
not satisfied:
Any response in WBC or platelet count without
progression in anemia, splenomegaly, or
constitutional symptoms
No response Any response that does not satisfy minor response
Table 5. Reference value of bone marrow cellularity in
selected age groups
Age, y Percent hematopoietic area*
20-30 60-70
40-60 40-50
70 or older 30-40
*The cellularity should be measured as percent hematopoietic area, measured
by disregarding the first 2 subcortical bone marrow lacunae, if hypocellular.18
Table 6. Grading of bone marrow fibrosis
Grading Description*
MF-0 Scattered linear reticulin with no intersections (crossovers)
corresponding to normal bone marrow
MF-1 Loose network of reticulin with many intersections, especially in
perivascular areas
MF-2 Diffuse and dense increase in reticulin with extensive
intersections, occasionally with focal bundles of collagen
and/or focal osteosclerosis
MF-3 Diffuse and dense increase in reticulin with extensive
intersections and coarse bundles of collagen, often
associated with osteosclerosis
*The quality of the reticulin stain should be assessed by detection of normal
staining in vessel walls as internal control. The degree of myelofibrosis should be
assessed by disregarding lymphoid nodules and vessels and disregarding fibers
framing adipocytes. Areas of prominent scleredema and/or scarring should be
included in the overall grading of myelofibrosis. Fiber density should be assessed in
hematopoieitc areas.18
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potentially curative therapy, and the cytogenetic analysis is a good
marker of disease modification.
We believe that the response criteria presented in this paper are
a promising new tool for monitoring disease activity and for
assessing therapeutic outcomes in patients with MMM. These
criteria will provide a means to compare the results from different
patient cohorts and are recommended to facilitate communication
within the scientific community.
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